For the second quarter of 2026, analysts anticipate a consensus revenue of $0.05 million and an EPS of -$0.87, while the current price of $2.86 sits significantly below the $19.58 average analyst target.
Investors are primarily focused on management's progress in securing a strategic partnership for the Phase 3 development of its lead candidate, neflamapimod, for the treatment of dementia with Lewy bodies.
Recent corporate momentum includes the completion of enrollment for a Phase 2a frontotemporal dementia study and the extension of the company's cash runway through the third quarter of 2027 following recent equity financings.
Positive biomarker data presented at the AAIC 2026 conference has further bolstered confidence in neflamapimod's efficacy, making the partnership search a critical catalyst for the stock.